Single agent chemotherapy with weekly docetaxel vs combination chemotherapy in second-line treatment of advanced non small cell lung cancer

Trial Profile

Single agent chemotherapy with weekly docetaxel vs combination chemotherapy in second-line treatment of advanced non small cell lung cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2012

At a glance

  • Drugs Capecitabine; Docetaxel; Gemcitabine; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms DISTAL-2
  • Most Recent Events

    • 01 Feb 2009 Primary endpoint 'overall Survival duration' has not been met.
    • 01 Feb 2009 Results reported in Lung Cancer.
    • 26 May 2008 Results presented at ASCO 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top